KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Total Debt (2018 - 2025)

Takeda Pharmaceutical (TAK) has 8 years of Total Debt data on record, last reported at $7.2 billion in Q1 2025.

  • For Q1 2025, Total Debt rose 1.26% year-over-year to $7.2 billion; the TTM value through Mar 2025 reached $7.2 billion, up 1.26%, while the annual FY2025 figure was $7.2 billion, 1.31% down from the prior year.
  • Total Debt reached $7.2 billion in Q1 2025 per TAK's latest filing, up from $7.1 billion in the prior quarter.
  • Across five years, Total Debt topped out at $37.3 billion in Q1 2022 and bottomed at $6.6 billion in Q1 2023.
  • Average Total Debt over 5 years is $13.1 billion, with a median of $7.2 billion recorded in 2025.
  • Peak YoY movement for Total Debt: skyrocketed 415.93% in 2022, then tumbled 82.3% in 2023.
  • A 5-year view of Total Debt shows it stood at $7.2 billion in 2021, then surged by 415.93% to $37.3 billion in 2022, then crashed by 82.3% to $6.6 billion in 2023, then increased by 7.77% to $7.1 billion in 2024, then increased by 1.26% to $7.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $7.2 billion in Q1 2025, $7.1 billion in Q1 2024, and $6.6 billion in Q1 2023.